Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Leukemia

Volumn 27, Issue 10, 2013, Pages 2081-2083

  Takahashi, K ^a,b   Jabbour, E ^a   Wang, X ^a   Luthra, R ^a   Bueso Ramos, C ^a   Patel, K ^a   Pierce, S ^a   Yang, H ^a   Wei, Y ^a   Daver, N ^a   Faderl, S ^a   Ravandi, F ^a   Estrov, Z ^a   Cortes, J ^a   Kantarjian, H ^a   Garcia Manero, G ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW; CANCER GROWTH; CANCER RISK; CAPILLARY ELECTROPHORESIS; CODON; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MYELODYSPLASTIC SYNDROME; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84885606356     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.165     Document Type: Letter

References (16)

1. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376-3382.
2. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098.
3. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
4. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
5. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744-752.
6. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013; 88: 56-59.
7. Al-Kali A, Quintas-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013; 88: 365-369.
8. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466-475.
9. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994; 8: 1331-1336.
10. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528-1532.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
12. Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012; 7: e42334.
13. Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134: 302-306.
14. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA et al. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-
15. internal tandem duplication mutation. Blood 2013; 121: 4655-4662.
16. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538-543.